364 related articles for article (PubMed ID: 25982595)
1. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
[TBL] [Abstract][Full Text] [Related]
2. Update of the Position Paper of the Spanish Society of Rheumatology on Biosimilar Drugs.
Abad Hernández MÁ; Andreu JL; Balsa Criado A; Díaz-González F; Moreno Muelas JV; Queiro Silva R; Gómez-Reino JJ
Reumatol Clin (Engl Ed); 2021 Mar; 17(3):160-169. PubMed ID: 31054806
[TBL] [Abstract][Full Text] [Related]
3. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
[TBL] [Abstract][Full Text] [Related]
4. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars in pediatric rheumatology and their introduction into routine care.
Aragon Cuevas O; Hedrich CM
Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.
Espinosa Morales R; Díaz Borjón A; Barile Fabris LA; Esquivel Valerio JA; Medrano Ramírez G; Arce Salinas CA; Barreira Mercado ER; Cardiel Ríos MH; Díaz Jouanen E; Flores Murrieta FJ; Fraga Mouret A; Garza Elizondo MA; Luján Estrada M; Muñoz Barradas FJ; Talavera Piña JO; Vera Lastra OL;
Reumatol Clin; 2013; 9(2):113-6. PubMed ID: 23395225
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars in rheumatology: recommendations for regulation and use in Middle Eastern countries.
El Zorkany B; Al Ani N; Al Emadi S; Al Saleh J; Uthman I; El Dershaby Y; Mounir M; Al Moallim H
Clin Rheumatol; 2018 May; 37(5):1143-1152. PubMed ID: 29411181
[TBL] [Abstract][Full Text] [Related]
8. Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease.
Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
Rev Esp Enferm Dig; 2013 Jan; 105(1):37-43. PubMed ID: 23548008
[TBL] [Abstract][Full Text] [Related]
9. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines.
Martínez-López de Castro N; Matilla-Fernández MB; Fraga-Fuentes MD; Mangues-Bafalluy I; Asensi-Díez R; Cajaraville-Ordoñana G
Farm Hosp; 2018 Jul; 42(4):180-183. PubMed ID: 29959844
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
Schaeverbeke T; Pham T; Richez C; Wendling D
Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
[No Abstract] [Full Text] [Related]
11. Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
[TBL] [Abstract][Full Text] [Related]
12. The advent of biosimilar therapies in rheumatology--"O brave new world".
Scheinberg MA; Kay J
Nat Rev Rheumatol; 2012 Jun; 8(7):430-6. PubMed ID: 22664834
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in rheumatology: understanding the rigor of their development.
Goel N; Chance K
Rheumatology (Oxford); 2017 Feb; 56(2):187-197. PubMed ID: 27241704
[TBL] [Abstract][Full Text] [Related]
14. [Biosimilars in rheumatology. Development and results of clinical trials].
Alten R
Z Rheumatol; 2015 Oct; 74(8):682-8. PubMed ID: 26347121
[TBL] [Abstract][Full Text] [Related]
15. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
17. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
